Drug resistance in ovarian cancer: From the laboratory to the clinic

Obstetrics and Gynecology

Volumn 92, Issue 2, 1998, Pages 312-319

  Sood, Anil K ^a   Buller, Richard E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ALKYLATING AGENT; BUTHIONINE SULFOXIMINE; CALCIUM ANTAGONIST; CALMODULIN INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; ETACRYNIC ACID; GLYCOPROTEIN P; TAMOXIFEN DERIVATIVE; VERAPAMIL;

CANCER CHEMOTHERAPY; DNA REPAIR; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG EXCRETION; DRUG TARGETING; GENE EXPRESSION; GENE THERAPY; IMMUNE RESPONSE; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 0032145449     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(98)00184-7     Document Type: Review

References (60)

1. 1. Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steven A. National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients' survival. Cancer 1993; 72:3663-70.
2. 2. McGowan L. Patterns of care in carcinoma of the ovary. Cancer 1993;71:628-33.
3. 3. McGuire WP, Hoskins WJ, Brady MF, Fucera PR, Partridge EE, Look KY, et al. Cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. 4. Li GC, Hahn GM. Ethanol-induced tolerance to heat and to adriamycin. Nature 1978;274:699-701.
5. 5. Li GC. Heat shock proteins: Role in thermotolerance, drug resistance, and relationship to topoisomerases. NCI Monogr 1987;4:99-103.
6. 6. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophysic Acta 1976;455:152-62.
7. 7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan J, Willingham MC. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;85:7735-8.
8. 8. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain-barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
9. 9. Holzmayer TA, Hilsenbeck S, von Hoff DD, Robinson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992;84:1486-91.
10. 10. Rubin SC, Finstad CL, Hoskins WJ, Saigo PF, Provencher DM, Federici MG, et al. Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 1990;163:69-73.
11. 11. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-6.
12. 12. Zaman GJ, Versantvoort CH, Smith JJ, Eijdems EW, de Haas M, Smith AJ, et al. Analysis of the expression of MRP, the gene for a new putative trans-membrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993;53:1747-50.
13. 13. Izquierdo MA, van der Zee AGJ, Vermerken JB, Vander Valk P, Belien JA, Giaccone G, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230-7.
14. 14. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991;87:772-7.
15. 15. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J. Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients. Anticancer Res 1989;9:1301-12.
16. 16. Mistry P, Kelland LR, Abel G, Sidhar S, Harrop KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991;64:215-20.
17. 17. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-67.
18. 18. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
19. 19. Kaye SB, Lewis CR, Duncan PJ, Gordon HK, Kitchener HC, Cruickshank DJ, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340:329-33.
20. 20. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996;14:2113-9.
21. 21. Buller RE, Vasilev S, DiSaia PJ. CA125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990's. Am J Obstet Gynecol 1996;174:1241-54.
22. 22. Antman KH, Souhami RL. High-dose chemotherapy in solid tumors. Ann Oncol 1993;4(suppl):S29-S44.
23. 23. Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, et al. A phase II trial of high-dose mitoxantrone, carboplatin and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcionoma: Analysis of risk factors for clinical outcome. Gynecol Oncol 1995;57:278-85.
24. 24. Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N, et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosplamide, and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma. J Clin Oncol 1994;12:176-83.
25. 25. Aksentijevich I, Pastan I, Lunardi-Iskandar Y, Gallo RC, Gottesman MM, Thierry AR. In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum Gene Ther 1996;7:111-22.
26. 26. Hegewisch-Becker S, Hanania EG, Fu S, Korbling M, Deisseroth AB, Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: Use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 1995;90:876-83.
27. 27. Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. Hum Gene Ther 1994;5:1507-22.
28. 28. Tsuruo T, Iida H, Tsukagoshi S, Sakurai J. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1982;41:1967-72.
29. 29. Toffoli G, Simone F, Corona G, Raschack M, Cappelletto B, Gigante M, et al. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. Biochem Pharmacol 1995;50: 1245-55.
30. 30. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7.
31. 31. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, et al. Multidrug resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
32. 32. Hendrick AM, Harris AL, Cantwell BMJ. Verapamil with mitoxantrone for advanced ovarian cancer: A negative phase II trial. Ann Oncol 1991;2:71-2.
33. 33. Echizen H, Brecht T, Niedergesass S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 1985;109:210-7.
34. 34. Thurlimann B, Kroger N, Greiner J, Mross K, Schuller J, Schernhammer E, et al. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. J Cancer Res Clin Oncol 1995;121(Suppl 3):R3-6.
35. 35. Kornek G, Raderer M, Schenk T, Pidlich J, Schulz F, Globitz S, et al. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer 1995;76:1356-62.
36. 36. Miller RL, Bukowski RM, Budd GT, Purris J, Weick JK, Shepard K, et al. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor trifluoperazine: A phase I/II trial. J Clin Oncol 1988;5:880-8.
37. 37. Murren JR, Durivage HJ, Buzaid AC, Reiss M, Flynn SD, Carter D, et al. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer. Cancer Chemother Pharmacol 1996;38:65-70.
38. 38. Ercoli A, Scambia G, De Vincenzo R, Alimonti A, Petrucci F, Fattorossi A, et al. Tamoxifen synergizes the antiproliferative effect of cisplatin in human ovarian cancer cells: Enhancement of DNA platination as a possible mechanism. Cancer Lett 1996;108:7-14.
39. 39. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 1995;9:1631-7.
40. 40. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991;68:269-71.
41. 41. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, DuBeshter B. Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996;62:4-6.
42. 42. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, et al. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer: A phase I/II study. Cancer 1990;9:1895-902.
43. 43. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, et al. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993;11:1957-68.
44. 44. O'Dwyer PJ, Hamilton TC, Young RC, LaCreta FP, Carp N, Tew D, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical endpoints. J Natl Cancer Inst 1992;84:264-7.
45. 45. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halfherr T, et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996;14:249-56.
46. 46. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991; 51:6059-65.
47. 47. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986;77:1405-8.
48. 48. Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 1986;54:235-8.
49. 49. Manetta A, Boyle J, Berman ML, DiSaia PJ, Lentz S, Liao SY, et al. Cyclosporin enhancement of cisplatin chemotherapy in patient with refractory gynecologic cancer. Cancer 1994;73:196-9.
50. 50. Chambers SK, Davis CA, Schwartz PE, Kohorn EI, Chambers JT. Modulation of platinum sensitivity and resistance by Cyclosporin A in refractory ovarian and fallopian tube cancer patients: A phase II study. Clin Cancer Res 1996;2:1693-7.
51. 51. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive Cyclosporin. Eur J Cancer 1991; 27:1639-42.
52. 52. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of p-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Res 1991;51:4226-33.
53. 53. Boesch D, Loor F. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs 1994;5:229-38.
54. 54. Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother Pharmacol 1992;29:195-200.
55. 55. Evans CH, Baker PD. Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin. Cancer Res 1992;52:5893-9.
56. 56. Walther W, Stein U. Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: Increased cytotoxicity of MDR relevant drugs. J Cancer Res Clin Oncol 1994;120:471-8.
57. 57. Bonavida B, Tsuchitani T, Zighelboim J, Berek JS. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, doxorubicin in ovarian cancer cells. Gynecol Oncol 1990;38:333-9.
58. 58. Vigani A, Chiara S, Miglietta L, Repetto L, Conte PF, Cimoli G, et al. Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity. Gynecol Oncol 1991;41:52-5.
59. 59. Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte P, et al. Potentiation of tumor necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer 1993;29A:1157-61.
60. 60. Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996;88:1383-92.